Title

IMAGO

Chief Investigator: 
Dr Simon Lord

 

ISRCTN Identifier: ISRCTN86522205

Sponsor: University of Oxford

A single arm exploratory study examining the feasibility of imaging glioblastoma pH using CEST MRI

STUDY DESIGN

Single arm exploratory

STUDY POPULATION

Previously untreated glioblastoma patients scheduled for resection or debulking.

STUDY STATUS

In set-up

STUDY SCHEMA

INCLUSION CRITERIA

  1. Participant is willing, capable of cooperating with the protocol and able to give informed consent for participation in the study.
  2. Male or Female, aged 18 years or above.
  3. Diagnosed with glioblastoma and scheduled for neurosurgical resection or debulking.

EXCLUSION CRITERIA

  1. Intolerant of MRI brain (for example: claustrophobia).
  2. MRI brain contraindicated (for example: implanted electric and electronic devices, heart pacemakers, insulin pumps, implanted hearing aids, neuostimulators, intracranial metal clips, metallic bodies in the eye).
  3. Prior treatment for glioblastoma.
  4. Pregnancy.
  5. Other psychological, social or medical condition that the investigator considers would make the patient a poor trail candidate or could interfere with protocol compliance or the interpretation of trial results.

PRIMARY OBJECTIVE

To evaluate CEST contrast image obtained from CEST MRI in glioblastoma

SECONDARY OBJECTIVES

  • Explore if measurement of tumour protein levels relates to CEST MRI imaging signal
  • Explore if measurement of tumour pH relates to CEST MRI imaging signal
  • Explore if hypoxia relates to CEST MRI imaging signal
  • Explore if ASL MRI perfusion imaging signal relates to CEST MRI imaging signal

IMAGO Trial Office (OCTO)

General Enquiries:

Tel: +44 (0)1865 617 083, Fax: +44 (0)1865 617 010

About Us
We aim to enhance clinical and basic cancer research in Oxford with the ultimate goal of increasing cancer cure rates.
Research
In Oxford, we have a great wealth of broad-ranging expertise and a powerful network of cancer researchers.
Study With Us
Our graduate training programmes for both scientists and clinicians are internationally recognised.